Gilead Sciences, Inc.

NasdaqGS:GILD Stock Report

Market Cap: US$115.1b

Gilead Sciences Valuation

Is GILD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GILD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GILD ($92.38) is trading below our estimate of fair value ($218.54)

Significantly Below Fair Value: GILD is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GILD?

Key metric: As GILD is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GILD. This is calculated by dividing GILD's market cap by their current revenue.
What is GILD's PS Ratio?
PS Ratio4.1x
SalesUS$28.30b
Market CapUS$115.13b

Price to Sales Ratio vs Peers

How does GILD's PS Ratio compare to its peers?

The above table shows the PS ratio for GILD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.1x
VRTX Vertex Pharmaceuticals
11.2x8.6%US$120.6b
AMGN Amgen
4.5x2.3%US$147.0b
REGN Regeneron Pharmaceuticals
5.8x6.8%US$83.2b
SGEN Seagen
18.8x22.6%US$43.2b
GILD Gilead Sciences
4.1x2.5%US$115.1b

Price-To-Sales vs Peers: GILD is good value based on its Price-To-Sales Ratio (4.1x) compared to the peer average (10.1x).


Price to Sales Ratio vs Industry

How does GILD's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.4x1.2%US$22.94b
MRNA Moderna
3.2x6.6%US$16.49b
INCY Incyte
3.3x9.0%US$13.97b
ALKS Alkermes
3.3x-0.7%US$5.01b
GILD 4.1xIndustry Avg. 10.2xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GILD is good value based on its Price-To-Sales Ratio (4.1x) compared to the US Biotechs industry average (10.2x).


Price to Sales Ratio vs Fair Ratio

What is GILD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GILD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.1x
Fair PS Ratio8.1x

Price-To-Sales vs Fair Ratio: GILD is good value based on its Price-To-Sales Ratio (4.1x) compared to the estimated Fair Price-To-Sales Ratio (8.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GILD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$92.38
US$99.07
+7.2%
12.6%US$125.00US$73.00n/a27
Dec ’25US$92.58
US$97.28
+5.1%
12.8%US$125.00US$69.00n/a28
Nov ’25US$89.51
US$87.94
-1.8%
13.9%US$123.00US$69.00n/a28
Oct ’25US$83.94
US$83.54
-0.5%
14.1%US$119.00US$68.50n/a27
Sep ’25US$79.00
US$83.43
+5.6%
14.1%US$119.00US$68.50n/a27
Aug ’25US$76.49
US$82.47
+7.8%
15.1%US$119.00US$67.00n/a27
Jul ’25US$68.64
US$82.97
+20.9%
14.2%US$119.00US$67.00n/a26
Jun ’25US$64.27
US$82.70
+28.7%
14.0%US$117.00US$67.00n/a26
May ’25US$65.51
US$83.69
+27.8%
13.0%US$117.00US$69.00n/a27
Apr ’25US$72.88
US$86.45
+18.6%
12.6%US$121.00US$69.00n/a26
Mar ’25US$72.31
US$87.86
+21.5%
12.5%US$121.00US$69.00n/a27
Feb ’25US$78.16
US$89.97
+15.1%
11.9%US$116.00US$69.00n/a27
Jan ’25US$81.01
US$90.15
+11.3%
11.9%US$116.00US$69.00n/a27
Dec ’24US$77.65
US$90.39
+16.4%
11.7%US$116.00US$71.00US$92.5827
Nov ’24US$80.19
US$90.95
+13.4%
11.2%US$116.00US$71.00US$89.5126
Oct ’24US$74.94
US$91.33
+21.9%
10.8%US$116.00US$71.00US$83.9426
Sep ’24US$76.65
US$91.75
+19.7%
10.3%US$116.00US$80.00US$79.0024
Aug ’24US$75.68
US$91.64
+21.1%
10.1%US$115.00US$77.00US$76.4925
Jul ’24US$77.07
US$92.60
+20.2%
9.8%US$115.00US$77.00US$68.6425
Jun ’24US$76.21
US$92.59
+21.5%
9.8%US$115.00US$77.00US$64.2725
May ’24US$81.42
US$92.56
+13.7%
8.8%US$115.00US$80.00US$65.5125
Apr ’24US$82.97
US$91.23
+10.0%
9.7%US$115.00US$77.00US$72.8822
Mar ’24US$79.59
US$92.17
+15.8%
10.4%US$115.00US$77.00US$72.3123
Feb ’24US$84.00
US$87.71
+4.4%
12.4%US$111.00US$63.00US$78.1624
Jan ’24US$85.85
US$84.79
-1.2%
13.0%US$105.00US$63.00US$81.0124
Dec ’23US$87.90
US$82.25
-6.4%
12.2%US$105.00US$63.00US$77.6524

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies